新天藥業(002873.SZ):公司OTC市場到2022年佔總營收的比例已經達到33%以上
格隆匯6月9日丨新天藥業(002873.SZ)接受機構調研、現場參觀,問答環節中,就“針對和顏坤泰膠囊的銷售目標,院端和OTC的佔比如何?”
公司回覆稱,答:和顏®坤泰膠囊系公司主打獨家專利品種、基藥、醫保甲類品種,是國內唯一改善卵巢功能衰退的中成藥、已進入多項教科書、共識和診療指南,是公司婦科類重磅品種。
公司OTC市場自2018年開始從無到有,到2022年佔總營收的比例已經達到33%以上,發展勢頭良好,隨着公司在OTC渠道端的持續投入與營銷策略的發力,及女性青春管理與生殖健康“和顏”中藥商業品牌的進一步投放與市場深入,預計該佔比在未來週期裏會逐年遞增,公司的產品品牌影響力及整體發展力等都已經進入一個全新的發展增長週期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.